Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Nichols

Showing results (261-270 of 331) with videos related to

Pageof 34
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2018
Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort StudyMatthew R Crull, Ranjani Somayaji, Kathleen J Ramos, et al.
Obesity (Silver Spring, Md.)|November 2, 2022
Cost-effectiveness of a motivational interviewing obesity intervention versus usual care in pediatric primary care officesSusan J Woolford, Kenneth Resnicow, Matthew M Davis, et al.
Annals of the American Thoracic Society|March 7, 2019
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic FibrosisRanjani Somayaji, Renee Russell, Jonathan D Cogen, et al.
Sensors (Basel, Switzerland)|April 5, 2020
A Syringe-Based Biosensor to Rapidly Detect Low Levels of Escherichia Coli (ECOR13) in Drinking Water Using Engineered BacteriophagesTroy C Hinkley, Spencer Garing, Paras Jain, et al.
Annals of the American Thoracic Society|January 31, 2014
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosisJerry A Nick, Samuel M Moskowitz, James F Chmiel, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2020
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development networkKelsie Pearson, Nicole Mayer-Hamblett, Christopher H Goss, et al.
Annals of the American Thoracic Society|July 30, 2020
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary ExacerbationsJonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
The Journal of Clinical Investigation|April 1, 1984
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 casesS E Shackney, A M Levine, R I Fisher, et al.
American Journal of Respiratory and Critical Care Medicine|August 27, 2024
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces <i>Aspergillus fumigatus</i> in Cystic FibrosisSarah J Morgan, David P Nichols, Windy Ni, et al.
Antimicrobial Agents and Chemotherapy|September 4, 2014
Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil productsSilvia M Caceres, Kenneth C Malcolm, Jennifer L Taylor-Cousar, et al.
Pageof 34

Showing results (261-270 of 331) with videos related to

Sort By:
Pageof 34
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 14, 2018
Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort StudyMatthew R Crull, Ranjani Somayaji, Kathleen J Ramos, et al.
Obesity (Silver Spring, Md.)|November 2, 2022
Cost-effectiveness of a motivational interviewing obesity intervention versus usual care in pediatric primary care officesSusan J Woolford, Kenneth Resnicow, Matthew M Davis, et al.
Annals of the American Thoracic Society|March 7, 2019
Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic FibrosisRanjani Somayaji, Renee Russell, Jonathan D Cogen, et al.
Sensors (Basel, Switzerland)|April 5, 2020
A Syringe-Based Biosensor to Rapidly Detect Low Levels of Escherichia Coli (ECOR13) in Drinking Water Using Engineered BacteriophagesTroy C Hinkley, Spencer Garing, Paras Jain, et al.
Annals of the American Thoracic Society|January 31, 2014
Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosisJerry A Nick, Samuel M Moskowitz, James F Chmiel, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 22, 2020
The impact of SARS-CoV-2 on the cystic fibrosis foundation therapeutics development networkKelsie Pearson, Nicole Mayer-Hamblett, Christopher H Goss, et al.
Annals of the American Thoracic Society|July 30, 2020
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary ExacerbationsJonathan D Cogen, Anna V Faino, Frankline Onchiri, et al.
The Journal of Clinical Investigation|April 1, 1984
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 casesS E Shackney, A M Levine, R I Fisher, et al.
American Journal of Respiratory and Critical Care Medicine|August 27, 2024
Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces <i>Aspergillus fumigatus</i> in Cystic FibrosisSarah J Morgan, David P Nichols, Windy Ni, et al.
Antimicrobial Agents and Chemotherapy|September 4, 2014
Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil productsSilvia M Caceres, Kenneth C Malcolm, Jennifer L Taylor-Cousar, et al.
Pageof 34